127 related articles for article (PubMed ID: 18316619)
1. Co-targeting insulin-like growth factor I receptor and HER2: dramatic effects of HER2 inhibitors on nonoverexpressing breast cancer.
Chakraborty AK; Liang K; DiGiovanna MP
Cancer Res; 2008 Mar; 68(5):1538-45. PubMed ID: 18316619
[TBL] [Abstract][Full Text] [Related]
2. Co-targeting the insulin-like growth factor I receptor enhances growth-inhibitory and pro-apoptotic effects of anti-estrogens in human breast cancer cell lines.
Chakraborty AK; Welsh A; Digiovanna MP
Breast Cancer Res Treat; 2010 Apr; 120(2):327-35. PubMed ID: 19337828
[TBL] [Abstract][Full Text] [Related]
3. 3,3'-diindolylmethane and paclitaxel act synergistically to promote apoptosis in HER2/Neu human breast cancer cells.
McGuire KP; Ngoubilly N; Neavyn M; Lanza-Jacoby S
J Surg Res; 2006 May; 132(2):208-13. PubMed ID: 16580691
[TBL] [Abstract][Full Text] [Related]
4. Modulation of HER2 expression by ferulic acid on human breast cancer MCF7 cells.
Chang CJ; Chiu JH; Tseng LM; Chang CH; Chien TM; Wu CW; Lui WY
Eur J Clin Invest; 2006 Aug; 36(8):588-96. PubMed ID: 16893382
[TBL] [Abstract][Full Text] [Related]
5. Induction of PDCD4 tumor suppressor gene expression by RAR agonists, antiestrogen and HER-2/neu antagonist in breast cancer cells. Evidence for a role in apoptosis.
Afonja O; Juste D; Das S; Matsuhashi S; Samuels HH
Oncogene; 2004 Oct; 23(49):8135-45. PubMed ID: 15361828
[TBL] [Abstract][Full Text] [Related]
6. Nordihydroguaiaretic acid (NDGA) inhibits the IGF-1 and c-erbB2/HER2/neu receptors and suppresses growth in breast cancer cells.
Youngren JF; Gable K; Penaranda C; Maddux BA; Zavodovskaya M; Lobo M; Campbell M; Kerner J; Goldfine ID
Breast Cancer Res Treat; 2005 Nov; 94(1):37-46. PubMed ID: 16142439
[TBL] [Abstract][Full Text] [Related]
7. Furanodienone induces cell cycle arrest and apoptosis by suppressing EGFR/HER2 signaling in HER2-overexpressing human breast cancer cells.
Li YW; Zhu GY; Shen XL; Chu JH; Yu ZL; Fong WF
Cancer Chemother Pharmacol; 2011 Nov; 68(5):1315-23. PubMed ID: 21461888
[TBL] [Abstract][Full Text] [Related]
8. Phosphorylated insulin-like growth factor-i/insulin receptor is present in all breast cancer subtypes and is related to poor survival.
Law JH; Habibi G; Hu K; Masoudi H; Wang MY; Stratford AL; Park E; Gee JM; Finlay P; Jones HE; Nicholson RI; Carboni J; Gottardis M; Pollak M; Dunn SE
Cancer Res; 2008 Dec; 68(24):10238-46. PubMed ID: 19074892
[TBL] [Abstract][Full Text] [Related]
9. Co-targeting ER and HER family receptors induces apoptosis in HER2-normal or overexpressing breast cancer models.
Chakraborty AK; Mehra R; Digiovanna MP
Anticancer Res; 2015 Mar; 35(3):1243-50. PubMed ID: 25750271
[TBL] [Abstract][Full Text] [Related]
10. Dysregulation of HER2/HER3 signaling axis in Epstein-Barr virus-infected breast carcinoma cells.
Lin JH; Tsai CH; Chu JS; Chen JY; Takada K; Shew JY
J Virol; 2007 Jun; 81(11):5705-13. PubMed ID: 17376931
[TBL] [Abstract][Full Text] [Related]
11. Insulin receptor isoform A and insulin-like growth factor II as additional treatment targets in human osteosarcoma.
Avnet S; Sciacca L; Salerno M; Gancitano G; Cassarino MF; Longhi A; Zakikhani M; Carboni JM; Gottardis M; Giunti A; Pollak M; Vigneri R; Baldini N
Cancer Res; 2009 Mar; 69(6):2443-52. PubMed ID: 19258511
[TBL] [Abstract][Full Text] [Related]
12. A mathematical model for the effects of HER2 overexpression on cell proliferation in breast cancer.
Eladdadi A; Isaacson D
Bull Math Biol; 2008 Aug; 70(6):1707-29. PubMed ID: 18648887
[TBL] [Abstract][Full Text] [Related]
13. Silk fibroin mediated delivery of liposomal emodin to breast cancer cells.
Cheema SK; Gobin AS; Rhea R; Lopez-Berestein G; Newman RA; Mathur AB
Int J Pharm; 2007 Aug; 341(1-2):221-9. PubMed ID: 17499461
[TBL] [Abstract][Full Text] [Related]
14. Preclinical antitumor activity of BMS-599626, a pan-HER kinase inhibitor that inhibits HER1/HER2 homodimer and heterodimer signaling.
Wong TW; Lee FY; Yu C; Luo FR; Oppenheimer S; Zhang H; Smykla RA; Mastalerz H; Fink BE; Hunt JT; Gavai AV; Vite GD
Clin Cancer Res; 2006 Oct; 12(20 Pt 1):6186-93. PubMed ID: 17062696
[TBL] [Abstract][Full Text] [Related]
15. Analysis of signaling pathways related to cell proliferation stimulated by insulin analogs in human mammary epithelial cell lines.
Shukla A; Grisouard J; Ehemann V; Hermani A; Enzmann H; Mayer D
Endocr Relat Cancer; 2009 Jun; 16(2):429-41. PubMed ID: 19153208
[TBL] [Abstract][Full Text] [Related]
16. Co-targeting HER2/ErbB2 and insulin-like growth factor-1 receptors causes synergistic inhibition of growth in HER2-overexpressing breast cancer cells.
Camirand A; Lu Y; Pollak M
Med Sci Monit; 2002 Dec; 8(12):BR521-6. PubMed ID: 12503030
[TBL] [Abstract][Full Text] [Related]
17. Si-Wu-Tang and its constituents promote mammary duct cell proliferation by up-regulation of HER-2 signaling.
Chang CJ; Chiu JH; Tseng LM; Chang CH; Chien TM; Chen CC; Wu CW; Lui WY
Menopause; 2006; 13(6):967-76. PubMed ID: 17075435
[TBL] [Abstract][Full Text] [Related]
18. Dual silencing of the EGF and type 1 IGF receptors suggests dominance of IGF signaling in human breast cancer cells.
Riedemann J; Sohail M; Macaulay VM
Biochem Biophys Res Commun; 2007 Apr; 355(3):700-6. PubMed ID: 17320820
[TBL] [Abstract][Full Text] [Related]
19. Expression of early placenta insulin-like growth factor in breast cancer cells provides an autocrine loop that predominantly enhances invasiveness and motility.
Brandt B; Kemming D; Packeisen J; Simon R; Helms M; Feldmann U; Matuschek A; Kersting C; Hinrichs B; Bidart JM; Bellet D; Bartkowiak K; Dankbar N; Dittmar T; Sauter G; Boecker W; Buerger H
Endocr Relat Cancer; 2005 Dec; 12(4):823-37. PubMed ID: 16322324
[TBL] [Abstract][Full Text] [Related]
20. Anti-tumor effect of honokiol alone and in combination with other anti-cancer agents in breast cancer.
Liu H; Zang C; Emde A; Planas-Silva MD; Rosche M; Kühnl A; Schulz CO; Elstner E; Possinger K; Eucker J
Eur J Pharmacol; 2008 Sep; 591(1-3):43-51. PubMed ID: 18588872
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
